NS0

NS0是一種源自非分泌型小鼠骨髓瘤（nonsecreting murine myeloma）的細胞系，目前應用於生物醫學研究和治療型蛋白質的商業生產^[1]。NS0是一種膽固醇依賴性的細胞系，由NSI/1的一個亞系產生，而該亞系僅產生輕鏈（英語：Immunoglobulin light chain）而不會產生重鏈（英語：Immunoglobulin heavy chain）^[2]^[3]。

歷史

在BALB/c小鼠體內分離出會分泌IgG1的MOPC21腫瘤後，從該腫瘤中分離出P3K細胞，並且發展成289-16細胞和P3-X63細胞。289-16細胞僅分泌輕鏈而不會分泌重鏈，並且被重命名為NSI/1。從該細胞系中分離出克隆，並鑑定出其為新的非分泌型細胞系，命名其為NS0/1^[2]^[4]。

用途

作為骨髓瘤細胞的NS0細胞是具有天然抗體的懸浮細胞，並且擁有淋巴母細胞（英語：Lymphoblast）形態。基因擴增（英語：Gene amplification）通常使用經GS轉染的NS0細胞進行選擇，以產生細胞系^[5]。GS-NS0是一種異源哺乳動物表達（英語：Heterologous expression）系統，可以表達重組蛋白。使用NS0細胞可以產生達利珠單抗（英語：Daclizumab）和依庫珠單抗（英語：Eculizumab）等具治療作用的抗體產品^[6]。

參考資料

^ Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效連結]}
^ ^2.0 ^2.1 Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效連結]}
^ Sato, JD; Cao, HT; Kayada, Y; Cabot, MC; Sato, GH; Okamoto, T; Welsh, CJ. Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium.. In vitro cellular & developmental biology : journal of the Tissue Culture Association. 1988-12, 24 (12): 1223–8 [2020-01-06]. PMID 3209588. doi:10.1007/bf02624194. ^{[永久失效連結]}
^ Galfrè, G; Milstein, C. Preparation of monoclonal antibodies: strategies and procedures.. Methods in enzymology. 1981, 73 (Pt B): 3–46 [2020-01-06]. PMID 7300683. doi:10.1016/0076-6879(81)73054-4. ^{[永久失效連結]}
^ Barnes, LM; Bentley, CM; Dickson, AJ. Characterization of the stability of recombinant protein production in the GS-NS0 expression system.. Biotechnology and bioengineering. 2001-05-20, 73 (4): 261–70 [2020-01-06]. PMID 11283909. doi:10.1002/bit.1059. ^{[永久失效連結]}
^ Wurm, FM. Production of recombinant protein therapeutics in cultivated mammalian cells.. Nature biotechnology. 2004-11, 22 (11): 1393–8 [2020-01-06]. PMID 15529164. doi:10.1038/nbt1026. ^{[永久失效連結]}

外部連結

Cellosaurus entry for NS0（頁面存檔備份，存於網際網路檔案館）

[1] Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效連結]}

[a-2] 2.0 ^2.1 Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效連結]}

[3] Sato, JD; Cao, HT; Kayada, Y; Cabot, MC; Sato, GH; Okamoto, T; Welsh, CJ. Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium.. In vitro cellular & developmental biology : journal of the Tissue Culture Association. 1988-12, 24 (12): 1223–8 [2020-01-06]. PMID 3209588. doi:10.1007/bf02624194. ^{[永久失效連結]}

[4] Galfrè, G; Milstein, C. Preparation of monoclonal antibodies: strategies and procedures.. Methods in enzymology. 1981, 73 (Pt B): 3–46 [2020-01-06]. PMID 7300683. doi:10.1016/0076-6879(81)73054-4. ^{[永久失效連結]}

[5] Barnes, LM; Bentley, CM; Dickson, AJ. Characterization of the stability of recombinant protein production in the GS-NS0 expression system.. Biotechnology and bioengineering. 2001-05-20, 73 (4): 261–70 [2020-01-06]. PMID 11283909. doi:10.1002/bit.1059. ^{[永久失效連結]}

[6] Wurm, FM. Production of recombinant protein therapeutics in cultivated mammalian cells.. Nature biotechnology. 2004-11, 22 (11): 1393–8 [2020-01-06]. PMID 15529164. doi:10.1038/nbt1026. ^{[永久失效連結]}

[1]

[2]

[3]

[4]

[5]

[6]